Global CRO Quintiles is planning to lay off about 270 workers, 1% of its payroll, in an effort to reduce "excess capacity," the company said.
After clearing roughly $4.2 billion in revenue in 2014, Quintiles is projecting another big year ahead, as the world's largest CRO counts on its backlog to keep business rolling in.
Quintiles founder Dennis Gillings is planning to step down from his role as chairman by the end of the year, endorsing the leadership of CEO Tom Pike and transitioning into a more advisory role at the world's largest CRO.
Quintiles has unveiled a new offering that combines its pharmacovigilance, label management, risk-benefit research and analytics into a single product, touting the service as a catch-all for approved drugs.
Data-gathering tools face a number of challenges including the integration of UDIs, differing device systems and components, and obtaining sufficient follow-up information, and capturing differences in provider experiences and training that could skew the outcomes data.
Quintiles, the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.
MonoSol Rx announced that the U.S. Patent and Trademark Office will decide by August 2015 whether BioDelivery Sciences International's BEMA drug delivery technology infringes on a patent protecting its Suboxone sublingual film.
Quintiles, the world's largest CRO, is dialing up its focus on nascent drugmakers, launching a biotech-focused service offering designed to meet the particular needs of the industry's seedlings without losing them in the Big Pharma shuffle.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.